Now live: Pro — the full 13F research suite for serious investorsSee pricing →
← Tracker

Institutional

BOONE CAPITAL MANAGEMENT LLC

CIK 0001882053
$326.4M
Reported AUM
13
Positions
Q1 2026
Period
2026-05-15
Filed

The Brief · BOONE CAPITAL MANAGEMENT LLC · Q1 2026

AI · grounded in 13F

BOONE CAPITAL MANAGEMENT LLC established a new position in TFX valued at $33.3M. The fund also opened new stakes in GRDN for $23.8M and ASTRAZENECA PLC for $21.7M. On the sell side, the manager closed its position in NBIX, reducing exposure by $21.5M. Additional exits included HQY and RAPT.

Portfolio · Q1 2026

MIRM$38.9MIONS$37.6MCI$36.7MMDT$34.5MTFX$33.3MBMRN$30.9MGRDN$23.8MAZN$21.7MUNH$21.4MBBIO$17.0MAVNS$16.6MKODBL

Top holdings

#StockIssuerPriceDay %1Y Gr.5Y Gr.Value% of bookΔ shares (QoQ)Status
1MIRMMIRUM PHARMACEUTICALS INC$108.50-3.63%108.58%567.72%$38.9M11.92%HELD
2IONSIONIS PHARMACEUTICALS INC$51.74-2.90%20.59%30.51%$37.6M11.51%HELD
3CITHE CIGNA GROUP$284.05-1.25%12.13%49.02%$36.7M11.24%HELD
4MDTMEDTRONIC PLC$84.23-1.73%-2.60%-26.16%$34.5M10.57%HELD
5TFXTELEFLEX INCORPORATED$131.81-0.37%15.04%-65.48%$33.3M10.22%HELD
6BMRNBIOMARIN PHARMACEUTICAL INC$59.42-1.92%2.19%-29.44%$30.9M9.48%HELD
7GRDNGUARDIAN PHARMACY SVCS INC$39.69-3.67%95.23%121.61%$23.8M7.28%HELD
8AZNASTRAZENECA PLC$169.27-1.21%17.87%62.01%$21.7M6.65%HELD
9UNHUNITEDHEALTH GROUP INC$419.72-0.42%80.64%9.66%$21.4M6.57%HELD
10BBIOBRIDGEBIO PHARMA INC$79.71-2.96%72.55%63.11%$17.0M5.21%HELD
11AVNSAVANOS MED INC127.60%-24.27%$16.6M5.09%HELD
12KODKODIAK SCIENCES INC$41.27-2.89%539.10%-54.87%$10.7M3.29%HELD
13TENXTENAX THERAPEUTICS INC$14.62-3.18%142.77%-99.41%$3.2M0.98%HELD

Source: SEC EDGAR · accession 0001214659-26-006448. 13F discloses long positions only — shorts, foreign equities, and options are excluded.